首页>
外国专利>
Genetic diagnosis for QT prolongation related adverse drug reactions
Genetic diagnosis for QT prolongation related adverse drug reactions
展开▼
机译:QT延长相关药物不良反应的遗传诊断
展开▼
页面导航
摘要
著录项
相似文献
摘要
The specification is directed to a method of diagnosing whether a subject is predisposed to an adverse reaction to one or more pharmaceutical agents which may induce a prolonged QT interval or acquired LQTS in that individual. The diagnosis is genetic analysis of at least two polymorphisms or mutations which the individual may have, which are associated with an increased risk for prolonged QT intervals or Torsades de Pointes (TdP). Genetic screening for determining the predisposition of prolonged QT intervals induced by a pharmaceutical agent is performed by identifying genetic polymorphisms or mutations located in at least two classes of genes, wherein the genes are (1) LQT genes, (2) altered sensitivity genes (e.g., MiRP1) or (3) increased exposure genes (e.g., MDR genes or P450 cytochrome genes). The specification is also directed to compositions and kits for determining such predispositions to adverse drug reactions.
展开▼
机译:本说明书针对一种诊断对象是否易受可能导致该个体延长QT间隔或获得性LQTS的对一种或多种药物的不良反应的方法。诊断是对个体可能具有的至少两个多态性或突变进行遗传分析,这与延长QT间隔或Torsades de Pointes(TdP)的风险增加有关。通过鉴定位于至少两类基因中的遗传多态性或突变来进行遗传筛选以确定由药剂诱导的延长QT间隔的易感性,其中基因是(1)LQT基因,(2)改变的敏感性基因(例如,MiRP1)或(3)增加暴露基因(例如MDR基因或P450细胞色素基因)。该说明书还针对用于确定这种不利药物反应易感性的组合物和试剂盒。
展开▼